472P - Effectiveness of nab-paclitaxel for malignant effusion in non-small cell lung cancer

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Cytotoxic agents
Non-Small-Cell Lung Cancer, Metastatic
Presenter YUKI Iwai
Citation Annals of Oncology (2016) 27 (suppl_9): ix139-ix156. 10.1093/annonc/mdw594
Authors Y. Iwai1, N. Koyama2, Y. Watanabe1, C. Miwa1, Y. Nagai1, S. Koyama1
  • 1Respiratory Medicine, Jichi Medical University Saitama Medical Center, 330-8503 - Saitama/JP
  • 2Oncology Medicine, Tokyo Medical University Hachioji Medical Center, 193-0998 - Tokyo/JP



Nanoparticle albumin-bound paclitaxel (nab-PTX) is currently one of standard therapeutic drugs for patients with advanced non-small cell lung cancer (NSCLC). Malignant effusion known as the common comorbidity in NSCLC evokes severe adverse events from chemotherapy and often fails to be controlled, leading to poor clinical outcome. The previous experimental reports showed that nab-PTX significantly reduced peritoneal metastasis and effusion associated with gastric and pancreatic cancers. In the clinical case reports, chemotherapy with nab-PTX plus platinum produced good response to metastatic thymic carcinoma with pleural effusion and peritoneal dissemination. However, there have been no reports about its effectiveness for NSCLC patients with malignant effusion. In this context, we investigated the effectiveness and safety of nab-PTX in NSCLC patients with effusion.


Forty patients who were treated with nab-PTX were enrolled in this study. The patients were classified into two groups according to the presence or absence of pleural or peritoneal effusion using computed tomography images. The clinicopathological characteristics and clinical outcomes were retrospectively evaluated with the statistical methods.


There were 26 patients with effusion (15 males; mean age 67) and 14 patients without effusion (11 males; mean age 70). The objective response rate was 38.5% in patients with effusion. There were no statistical differences in clinical features involving progression-free survival (PFS) (141 days vs 147 days) and adverse events between the two groups. The groups of squamous cell carcinoma and performance status (PS) 0-1 had significant PFS benefits compared with those of other histological types (260 days vs 141 days; p 


Chemotherapy with nab-PTX might be one of the potential therapeutic options for NSCLC patients coexisting malignant effusions.

Clinical trial indentification

Legal entity responsible for the study

Jichi Medical University Saitama Medical Center


Jichi Medical Univercity


All authors have declared no conflicts of interest.